Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Mankind Pharma Invests...

    Mankind Pharma Invests Rs 305 crore to launch Diagnostic Venture-Pathkind

    Written by savita thakur thakur Published On 2017-03-26T11:29:22+05:30  |  Updated On 26 March 2017 11:29 AM IST
    Mankind Pharma Invests Rs 305 crore to launch Diagnostic Venture-Pathkind

    NEW DELHI: After showing its worth in pharmaceutical industry, the Mankind pharma is all set to enter into the diagnostics market under its new venture- Pathkind Labs.


    The Delhi based mankind pharma is reported to have invested Rs. 305 crore its new venture -Pathkind Labs. Sanjeev Vashishta, former chief executive officer of SRL Diagnostics will be the leading chief executive of Pathkind Labs reports Business Standard.


    Explaining the need and importance of quality diagnostic healthcare in India specialy in rural areas, Sanjeev Vashishta former chief executive officer of SRL Diagnostics said, “We are introducing a sub-hub and spoke model as opposed to the hub and spoke model that others use."


    “There is a huge demand for quality diagnostics, especially in rural areas. Diagnostics can be used as preventive healthcare measure to reduce overall health expenditure.We want to leverage on this opportunity by providing quality services at affordable prices."


    Speaking about their initial work plan Vashishta told to ET that the company will initially start its operations from the northern region and plans to tap Uttar Pradesh, Uttarakhand and parts of Bihar in next one year. He further informed that the company will operate on a three-tier model of hub, sub-hub and multiple.


    The company will have a reference lab in Gurgaon, large network labs in metros or bigger cities, and smaller rapid response labs in tier-II cities.


    The company will focus more in Uttar Pradseh. Out of 11 large network labs, 8 will be opened in UP including in Lucknow, Varanasi, Meerut and Gorakhpur. Besides, Uttarakhand will have one and Bihar will have two large labs.


    Diagnostic ventureInvestmentMankind PharmapathkindPathkind LabsRs 305 CroreSanjeev VashishtaSRL Diagnostics
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok